Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AC Immune (ACIU) Non-Current Deffered Revenue: 2024-2025

Historic Non-Current Deffered Revenue for AC Immune (ACIU) over the last 2 years, with Sep 2025 value amounting to $3.4 million.

  • AC Immune's Non-Current Deffered Revenue fell 38.95% to $3.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.4 million, marking a year-over-year decrease of 38.95%. This contributed to the annual value of $3.4 million for FY2025, which is N/A change from last year.
  • Latest data reveals that AC Immune reported Non-Current Deffered Revenue of $3.4 million as of Q3 2025, which was up 77,605.62% from $4,344 recorded in Q2 2025.
  • AC Immune's 5-year Non-Current Deffered Revenue high stood at $5.7 million for Q2 2024, and its period low was $4,344 during Q2 2025.
  • Over the past 2 years, AC Immune's median Non-Current Deffered Revenue value was $3.9 million (recorded in 2025), while the average stood at $3.2 million.
  • Data for AC Immune's Non-Current Deffered Revenue shows a maximum YoY crashed of 99.92% (in 2025) over the last 5 years.
  • Quarterly analysis of 2 years shows AC Immune's Non-Current Deffered Revenue stood at $5,205 in 2024, then plummeted by 38.95% to $3.4 million in 2025.
  • Its Non-Current Deffered Revenue stands at $3.4 million for Q3 2025, versus $4,344 for Q2 2025 and $4.4 million for Q1 2025.